https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17408 Sat 24 Mar 2018 08:01:37 AEDT ]]> Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial mechanical function after reversion of atrial arrhythmias to sinus rhythm: reversal of tachycardia-mediated atrial cardiomyopathy with fish oils https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17407 Sat 24 Mar 2018 08:01:36 AEDT ]]> Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human pulmonary vein and left atrial electrophysiology in paroxysmal atrial fibrillation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17907 1 month before their procedure into a control group (n = 18) or a fish oil group (n = 18) in an unblinded fashion. The latter were supplemented with fish oil 6 g/day for a mean of 40 ± 12 days. Pulmonary venous and left atrial effective refractory periods (ERPs), PV conduction, and susceptibility to AF initiated within PVs were assessed. Compared to the control group, the fish oil group had (1) longer left-sided (p = 0.002) and right-sided (p = 0.001) pulmonary venous ERPs; (2) less dispersion of pulmonary venous ERPs (left PVs p = 0.001, right PVs p = 0.07); (3) longer left atrial ERPs (p = 0.02); (4) no difference in pulmonary venous conduction; (5) lower incidence of AF initiated from PVs during ERP testing (77% vs 31%, p = 0.02); and (6) prolongation of mean AF cycle length (p = 0.009) and shortest AF cycle length in PVs (p = 0.04). In conclusion, patients with PAF chronically supplemented with fish oils exhibit distinctive electrophysiologic properties including prolonged pulmonary venous and left atrial ERPs and decreased susceptibility to initiation AF from within PVs. These changes may in part explain the antifibrillatory effect of chronic omega-3 polyunsaturated fatty acid supplementation in patients with PAF.]]> Sat 24 Mar 2018 07:56:40 AEDT ]]> Effects of high dose intravenous fish oil on human atrial electrophysiology: implications for possible anti- and pro-arrhythmic mechanisms in atrial fibrillation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19402 Sat 24 Mar 2018 07:52:08 AEDT ]]> Effects of long-term omega-3 polyunsaturated fatty acid supplementation on paroxysmal atrial tachyarrhythmia burden in patients with implanted pacemakers: results from a prospective randomised study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19351 1 min was not significantly different between the groups (P = .9). There was a rebound increase in AT/AF burden in p3 in cross over patients (2.2% to 5.8%, P = .01) reaching a level similar to controls (crossover vs. controls, 5.8% vs. 4.3%, P = .63) and higher than those who continued fish oil for 12 months (crossover vs. continued intake 5.8% vs. 1.2%, P = .02). Fish oil patients had shorter duration episodes of AT/AF with no difference in frequency compared to controls. Conclusion: Long-term fish oil supplementation did not suppress AT/AF burden but may have attenuated its temporal progression related to aging and sinus node disease.]]> Sat 24 Mar 2018 07:52:02 AEDT ]]> Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23784 1 month prior to electrical cardioversion and continued thereafter reduces recurrence of persistent AF. Methods: This was an open-label, randomized study of 178 patients with persistent AF >1-month duration. Participants were assigned to control group (n = 87) or omega-3 group (6 g/d fish oil; n = 91) and underwent cardioversion 1 month later. Concurrent antiarrhythmic use of sotalol or amiodarone was permitted. Fish oil was continued till return of persistent AF or a maximum of 1 year. Intention-to-treat analysis was performed for the primary end point defined as the recurrence of persistent AF. Results: Mean duration of fish oil intake was 56 days precardioversion and a total of 242 days in follow-up. Eicosapentaenoic acid and docosahexaenoic acid, the active components of fish oils, were 1.8-fold and 2.1-fold higher, respectively, in the omega-3 group compared with controls at the time of cardioversion (P <.001). At 90 days, 38.5% of the patients receiving omega-3 fatty acid supplement had AF recurrence compared with 77.5% of the controls (hazard ratio [omega-3 vs control] 0.38; 95% confidence interval 0.27−0.56; P <.001). Omega-3 intake was associated with a significant reduction in AF recurrence with or without concurrent antiarrhythmic drugs. Conclusions: Omega-3 polyunsaturated fatty acid supplementation commenced >1 month prior to electrical cardioversion and continued thereafter reduces the recurrence of persistent AF. Randomized controlled trials on long-term fish oil supplementation are needed to confirm these findings.]]> Fri 21 Oct 2016 15:57:37 AEDT ]]>